IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10/507281

In re Patent Application of

Jean-Christophe LEROUX et al.

Application No.: 10/507,281

Filed: June 9, 2005

COMPOSITION HAVING GELLING For:

PROPERTIES FOR THE PROLONGED)

DELIVERY OF BIOACTIVE

SUBSTANCES

National Stage of International Appln. No.

PCT/FR03/00797

International Filing Date: March 12, 2003 Earliest Priority Date: March 12, 2002

MAIL STOP PCT

Group Art Unit:

Examiner:

Confirmation No.: 4230

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request consideration of the documents listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publication are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents listed on the accompanying Form PTO-1449 are in English except for WO 03/075885 and EP 1063007.

WO 03/075885 is the published version of PCT/FR03/00797, of which the present application is the U.S. national stage. The WO publication is of course not prior art herein. A full English translation of the PCT application was filed herein on September 10, 2004.

EP 1063007 was cited during the international phase of this application in the ISR and IPER, both of which were provided herein in French and English. An English-language

FIRST Information sclosure Statement Application No. 10/507,281
Attorney's Docket No. 017753-204
Page 2

abstract and patent family search is attached to the copy of EP 1063007 submitted herewith. Also attached to that copy is a brief statement of relevance. Applicants do not have an English translation of the reference.

Applicants have cited herein several U.S. patent documents in lieu of their foreign counterparts cited in the ISR and IPER. Thus, in place of WO 99/56725, applicants are citing its U.S. counterparts, Fanara et al. U.S. Patent Nos. 6,464,987 and 6,471,970. Also, in place of FR 2281162, applicants are citing the U.S. counterpart, Saito et al. U.S. Patent No. 3,969,087.

This statement, Form PTO-1449 and copies are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that the Examiner consider these papers and that an Examiner-initialed copy of the Form PTO-1449 be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date <u>June 9, 2005</u>

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620 Bv:

Mary Katherine Baumeister Registration No. 26,254

·	· ·	
Substitute for form 1449A/PTO & 1449B/PTO	Com	nple
FIRST	Application Number	10/507,281
INFORMATION DISCLOSURE	Filing Date	June 9, 2005
STATEMENT BY APPLICANT	First Named Inventor	Jean-Christophe LEROUX et al.
(use as many sheets as necessary)	Examiner Name	
Sheet 1 of 1	Attorney Docket Number	017753-204

			U.S. PATENT DOC	UMENTS								
Examiner Initials	Document Kind Code Name of Patentee or Applicant of Cited Document .							Issue/Publication Date (MM-DD-YYYY)				
	3,969,087		SAITO et al.						07-13-1976			
	6,306,383	B1	CRANDALL						10-23-2001			
	6,464,987	B1	FANARA et al.						10-15-2002			
	6,471,970	B1	FANARA et al.						10-29-2002			
	3,932,624		FULTON						01-13-1976			
	2001/0007673	A1	GOLDENBERG et al.			-		07-12-2001				
	5,575,815		SLEPIAN et al.					11-19-1996 02-05-2002				
	6,344,488	B1	CHENITE et al.									
			FOREIGN PATENT DO	CUMENTS								
	S								STATUS			
Examiner Initials	Document Number	Kind Code (if known)	I COUNTRY	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Spec Spec	
	03/075885	A1	wo	09-18-2003	X		4				5.7	
	99/13913	A2	wo	03-25-1999				X	X			
	97/15287	A1	wo	05-01-1997								
	94/08623	A1	wo	04-28-1994							İ	
	1 063 007	A1	EP	12-27-2000			Х	Х	X	Х		
			NON-PATENT LITERATUR	E DOCUMENTS								
Examiner Initials	serial, symp	osium, catalog, e	PITAL LETTERS), title of the a etc.), date, page(s), volume-iss p. 1556-1557, published by Ro	ue number(s), publisher,	city a	nd/or c	ountry w				nal,	
			mun., 2001, pp. 185-186, publiceutical Sciences, Vol. 88, No.							Cell	tical	
	Assn. & Wiley, East	ton, PA.					_					
	Pharmaceutical Ass	sn. & Wiley, East										
	JOHNSTON et al., a Parenteral Drug Ass		teral Science & Technology, Vo da, MD.	ol. 43, No. 6, November-	Decer	nber 19	189, pp.	279-28	6, put	olishe	d by	
	JOHNSTON et al., a Germany.	Pharmaceutical F	Research, Vol. 9, No. 3, 1992, p	pp. 425-434, published by	y Plen	ium Pu	olishing	Compa	ny, S	tuttga	art,	
	PEC et al., Journal Stuttgart, Germany.		al Sciences, Vol. 81, No. 7, Jul	y 1992, pp. 626-630, pub	lishe	d by Ple	enum Pi	ublishing	Con	npan	у,	
	MIYAZAKI et al., Jo	ournal of Controlle	ed Release, 56, 1998 pp. 75-83	3, published by Elsevier S	Scienc	e Publi	shers, A	Amsterd	am, F	lollar	ıd.	
	Couffin-Hoarau e Publishers, New		utical Research, Vol. 21, N	o. 3, March 2004, pp.	454-4	157, pu	ıblishe	d by Pl	enun	1		

Examiner		Date			1
Signature		Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

VA 726176.1